AdvanCell closed a $315 million Series D financing to advance its lead radiopharmaceutical candidate into late-stage development and expand US manufacturing capacity. The company said the funding supports clinical progression for a prostate cancer agent and increases throughput for radioisotope-based production. The round is framed as particularly important for radiopharma makers where the bottleneck is often manufacturing availability rather than only clinical execution. It also positions AdvanCell as a direct contender in the expanding radioligand market. Industry observers will watch follow-on milestones for the prostate program and whether the expanded manufacturing platform can translate financial scale into reliable supply for trial and commercial timelines.